ALAN EPSTEIN: Open Payments
NPI 1346211844 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$48,294 in 68 payments from 10 companies in 2025. Trend: 2023 $155,744 · 2024 $150,799 · 2025 $48,294
Speaker / faculty: $32,493Consulting: $11,952Travel & lodging: $2,216Food & beverage: $1,578Education: $55
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 14 | $16,096 |
| GlaxoSmithKline, LLC. | 3 | $11,050 |
| ABBVIE INC. | 16 | $7,478 |
| AstraZeneca Pharmaceuticals LP | 12 | $3,813 |
| SOBI, INC | 4 | $2,810 |
| Janssen Scientific Affairs, LLC | 1 | $2,565 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $2,073 |
| Invivyd Inc | 1 | $2,013 |
| Amgen Inc. | 14 | $379 |
| PFIZER INC. | 1 | $18 |
Products named: TREMFYA, BENLYSTA, SKYRIZI, SAPHNELO, PEMGARDA, RINVOQ, OTEZLA, UPLIZNA.
Industry payments across PA — which companies pay providers there.
